<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2006.21.6.1021</article-id><article-id pub-id-type="pmid">17179680</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><italic>GSTM1</italic> and <italic>GSTP1</italic> Polymorphisms as Potential Factors for Modifying the Effect of Smoking on Inflammatory Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jin-Hee</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Shin-Goo</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kwan-Hee</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Ji-Ho</given-names></name><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Eun-Hee</given-names></name><xref ref-type="aff" rid="A4">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Myung</surname><given-names>Seung-Kwon</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A5">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hong</surname><given-names>Yun-Chul</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A6">&#x000b6;</xref></contrib></contrib-group><aff id="A1"><label>*</label>Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>&#x02020;</label>Department of Occupational &#x00026; Environmental Medicine, Inha University Hospital, Incheon, Korea.</aff><aff id="A3"><label>&#x02021;</label>Department of Family Medicine, Inha University Hospital, Incheon, Korea.</aff><aff id="A4"><label>&#x000a7;</label>Department of Preventive Medicine, Ewha Womans University College of Medicine, Seoul, Korea.</aff><aff id="A5"><label>&#x02225;</label>Center for Cancer Prevention and Detection, National Cancer Center Hospital, Goyang, Korea.</aff><aff id="A6"><label>&#x000b6;</label>Institute of Environmental Medicine, SNUMRC, Seoul, Korea.</aff><author-notes><corresp> Address for correspondence: Yun-Chul Hong, M.D. Department of Preventive Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-799, Korea. Tel: +82.2-740-8394, Fax: +82.2-747-4830, <email>ychong1@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2006</year></pub-date><volume>21</volume><issue>6</issue><fpage>1021</fpage><lpage>1027</lpage><history><date date-type="received"><day>17</day><month>2</month><year>2006</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Inflammation has been known to be an important underlying condition for development of various diseases including cancer. The aims of this study were to investigate whether tobacco smoke exposure increases the level of inflammation biomarkers and the <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms are associated with inflammatory response due to tobacco smoke exposure. We measured urinary cotinine level in 300 healthy university students. Total serum TNF-&#x003b1; levels and blood WBC counts were determined to evaluate inflammatory response. Allelic loss of the <italic>GSTM1</italic> and the <italic>GSTP1</italic> (Ile105Val) polymorphism were determined by PCR and RFLP. Tobacco smoke exposure was found to be associated with increase of both TNF-&#x003b1; level and WBC count. Particularly, smokers with combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes showed higher TNF-&#x003b1; level than those with the other genotype combinations (<italic>p</italic>=0.07). This result suggests that smoking may induce inflammation measured as TNF-&#x003b1; level or WBC count and combinations of the <italic>GSTM1</italic> and <italic>GSTP1</italic> polymorphisms may modify the effect of smoking on serum TNF-&#x003b1; level.</p></abstract><kwd-group><kwd>Smoking</kwd><kwd>Inflammation</kwd><kwd>Tumor Necrosis Factor-alpha</kwd><kwd>Leukocytes</kwd><kwd>glutathione S-transferase M1</kwd><kwd>Glutathione S-Transferase pi</kwd><kwd>Polymorphism, Genetic</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Inflammation is a dynamic response of vascularized tissues to injury and an important part of the body's defense mechanisms (<xref ref-type="bibr" rid="B1">1</xref>). Although inflammation is importantly required for homeostasis, excessive inflammation may induce various diseases including cancer (<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B5">5</xref>). Cigarette smoking has been known to induce cancer in a variety of tissues including lung through chronic inflammation (<xref ref-type="bibr" rid="B6">6</xref>). Previous studies have shown that cigarette smoking induces proteins related in inflammation, so called inflammation markers (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Tumor necrosis factor alpha (TNF-&#x003b1;) and white blood cells (WBCs) are well known inflammatory markers. Cytokines such as TNF-&#x003b1; are important inducers of inflammatory response, and the existing evidence implicates the role of TNF-&#x003b1; in inflammatory pathways that increase a variety of diseases (<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B13">13</xref>). In one large prospective study (Honolulu Heart Program), persons with WBC count in highest tertile had 30% increased risk of dying from cancer compared with persons in the lowest tertile (<xref ref-type="bibr" rid="B14">14</xref>). Another prospective study has shown that elevation in WBC count within the clinically normal range is associated with increased risk of several chronic diseases related to inflammation (<xref ref-type="bibr" rid="B15">15</xref>). Therefore, it is believed that increased TNF-&#x003b1; level and WBC count play important roles in smoking-induced inflammation which could be associated with increased risk of diseases (<xref ref-type="bibr" rid="B16">16</xref>).</p><p>Glutathione S-transferase (GST) M1 and P1 are detoxification enzymes, which have a pivotal role in catalyzing the conjugation of glutathione (GSH) to electrophilic substrates (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Because of this function of GSTM1 and GSTP1, they may protect against inflammation and oxidative stress through detoxification of various toxic substances in tobacco smoke (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Several studies have demonstrated that individuals lacking the GSTM1 activity have increased risk of smoking-related diseases (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Moreover, the GSTP1 protein was reported to be very important in metabolism of many carcinogenic compounds including benzo[a]pyrene diolepoxide (BPDE) which is one of the most important carcinogenic metabolites in tobacco smoke (<xref ref-type="bibr" rid="B20">20</xref>).</p><p>The human <italic>GSTM1</italic> is polymorphic and its deletion is responsible for the existence of a null type lacking the enzyme function (<xref ref-type="bibr" rid="B23">23</xref>). Furthermore, a polymorphic site at codon 105 (A to G substitution replacing isoleucine with valine) of <italic>GSTP1</italic> is known to change the kinetic property of the enzyme in binding with a few of electrophilic substrates including PAH diolepoxides (<xref ref-type="bibr" rid="B24">24</xref>). For this reason, <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms may contribute to susceptibility to inflammation-related diseases. These results also suggest that <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms may be involved in the detoxification of toxic substances in cigarette smoke to change the levels of TNF-&#x003b1; and WBC, which are inflammatory markers. Therefore, in the present study we tried to investigate whether tobacco smoke exposure increases the level of inflammation biomarkers and the <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms are associated with inflammatory response due to tobacco smoke exposure.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Study population and sampling</title><p>A total of 300 students at Inha University, Incheon, Korea, were recruited during September 2002 after exclusion of students having conditions affecting inflammatory biomarkers such as inflammatory disorder or medication of anti-inflammatory drugs. Information on demographic characteristics and lifestyle habits including smoking and alcohol consumption were collected by trained interviewers using a structured questionnaire. We controlled fasting state by asking them for overnight fasting to participate in this study and samplings of blood and urine were done in the morning. After collecting venous blood samples from subjects, whole blood in a heparinized tube was kept at 4&#x02103; for counting of blood WBC and serum in a plain tube was separated by centrifugation within 4 hr and frozen at -70&#x02103; for the analysis of TNF-&#x003b1; level. In addition, urine was kept frozen at -20&#x02103; for the analysis of cotinine level. The study protocol was approved by the institutional review board at Inha University Hospital and written informed consent was provided by all study subjects.</p></sec><sec><title>Measurement of serum TNF-&#x003b1; levels and blood WBC counts</title><p>Serum TNF-&#x003b1; level was determined by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (R&#x00026;D Systems, Minneapolis, MN, U.S.A.). The detection limit of the assay was 0.12 pg/mL. In addition, the count of blood WBC was measured using cell counter.</p></sec><sec><title>Measurement of urinary cotinine levels</title><p>Urinary cotinine levels were determined for monitoring tobacco exposure. After urine samples were centrifuged to remove particulate matter, cotinine level was analyzed by a liquid phase radioimmunoassay method using the fundamental principles of a competitive reaction between antibodies and <sup>125</sup>I-labeled cotinine and urinary cotinine (DPC, Los Angeles, CA, U.S.A.). After allowing antigen-antibody reaction for 30 min, the fraction bound to antibody was precipitated and its radioactivity was measured for 1 min using Cobra D5010 Quantum, a gamma-counter (Packard, Meriden, CT, U.S.A.). Urinary cotinine level was adjusted to urine creatinine.</p></sec><sec><title>Genotyping assays</title><p>Genomic DNA was extracted from peripheral blood lymphocytes using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, U.S.A.), and analyzed using PCR and RFLP method for <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms. The 20 &#x000b5;L PCR reaction mixture used for <italic>GSTM1</italic> and <italic>GSTP1</italic> genotyping contained 10 mM of Tris-HCl (pH 9.0), 40 mM of KCl, 1.5 mM of MgCl<sub>2</sub>, 0.25 mM of each dNTP, 1 unit of <italic>Taq</italic> polymerase (Bioneer, Seoul, Korea), 20 pmole of the forward and reverse primers, and 50 ng of genomic DNA as a template. Amplifications were performed using the following conditions; initial denaturation at 94&#x02103; for 5 min, 35 cycles with denaturation at 94&#x02103; for 1 min, annealing at 65&#x02103; for 1 min, and extension at 72&#x02103; for 1 min, and then completion at 72&#x02103; for 7 min. PCR amplification of reaction mixtures was carried out using a thermal cycler, PTC-200 (MJ Research, Watertown, MA, U.S.A.).</p><p><italic>GSTM1</italic> and <italic>GSTP1</italic> genotypes were determined using a multiplex PCR method. Primer sets for <italic>GSTM1</italic> and <italic>GSTP1</italic> genes were used for the amplification reaction. The primers designed were: <italic>GSTM1</italic>-forward, 5'-GAACTCCCTGAAAAGCTAAAGC-3', <italic>GSTM1</italic>-reverse, 5'-GTTGGGCTCAAATATACGGTGG-3'; <italic>GSTP1</italic>-forward, 5'-CCAGTGACTGTGTGTTGATC-3', <italic>GSTP1</italic>-reverse, 5'-CAACCCTGGTGCAGATGCTC-3'. The PCR products were digested with restriction enzyme <italic>BsmA</italic> I at 55&#x02103; for 3 hr for <italic>GSTP1</italic> genotyping and detected by electrophoresis on 3% 3:1 NuSieve/agarose gel (Cambrex Bio Science, Rockland, ME, U.S.A.). Genotyping of the <italic>GSTM1</italic> gene was determined based on the presence of a 215-bp product. For the genotyping of the <italic>GSTP1</italic> gene, the 189-bp PCR product remained intact for the A allele, but was cleaved into smaller fragments of 149-bp and 40-bp in the case of the G allele. For confirming the analyses, ten percent of the samples were randomly chosen and genotyped again, producing identical results.</p></sec><sec><title>Statistical analysis</title><p>Means and the distributions of characteristic variables according to smoking status were compared using the t-test or chi-square test. The t-test was used to analyze relationships between TNF-&#x003b1; level or WBC count and subject characteristics such as age, sex, body mass index (BMI), smoking status, cotinine level, and the <italic>GSTM1</italic> and <italic>GSTP1</italic> genotypes. The effects of smoking on total serum TNF-&#x003b1; level and blood WBC count were evaluated by linear regression analysis. Correlation between smoking amounts obtained from questionnaire and urinary cotinine level was evaluated by Spearman's and Kendall's rank correlations as well as Pearson's correlation analysis. Analysis of variance (ANOVA) was used to evaluate the effects of genotype combinations on inflammatory markers according to smoking amount or cotinine level. For smokers, pack year value was calculated to indicate cumulative cigarette dose (pack years=[cigarettes/day&#x000f7;20]&#x000d7;years of smoking). A probability level of 0.05 was used as the criterion of statistical significance based on two-sided test. SAS, version 8.1 (SAS institute Inc., Cary, NC, U.S.A.) was used for the statistical analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The demographic characteristics of the study subjects by smoking status are listed in <xref ref-type="table" rid="T1">Table 1</xref>. Mean pack year of smokers was 3.56 (range, 0.15-9.00). BMI and the <italic>GSTM1</italic> genotype showed no significant differences with respect to smoking status. However, urinary cotinine level, age, sex, alcohol consumption, and the <italic>GSTP1</italic> genotype were found to be significantly different in distribution according to smoking status (cotinine, <italic>p</italic>&#x0003c;0.01; age, <italic>p</italic>&#x0003c;0.01; sex, <italic>p</italic>&#x0003c;0.01; alcohol consumption, <italic>p</italic>&#x0003c;0.01; and GSTP1, <italic>p</italic>=0.02, respectively).</p><p>Total serum TNF-&#x003b1; levels and blood WBC counts according to age, sex, BMI, alcohol consumption, and <italic>GSTM1</italic> and <italic>GSTP1</italic> genotypes are listed in <xref ref-type="table" rid="T2">Table 2</xref>. Age, sex, and alcohol consumption were not found to be significantly related to TNF-&#x003b1; level or WBC count. Obesity was found to be significantly associated with increase of WBC count (<italic>p</italic>&#x0003c;0.01), but the observed increase of TNF-&#x003b1; with obesity did not reach statistical significance (<italic>p</italic>=0.08). Subjects with the <italic>GSTM1</italic> null genotype had significantly higher TNF-&#x003b1; level than those with the <italic>GSTM1</italic> present genotype (<italic>p</italic>=0.04). However, the <italic>GSTM1</italic> genotype did not affect WBC count (<italic>p</italic>=0.82). Subjects with the <italic>GSTP1</italic> AG or GG genotype had significantly higher WBC count than those with <italic>GSTP1</italic> AA genotype (<italic>p</italic>=0.04). TNF-&#x003b1; level was also higher in subjects with the <italic>GSTP1</italic> AG or GG genotype than those with the <italic>GSTP1</italic> AA genotype, although this difference did not reach statistical significance (<italic>p</italic>=0.38).</p><p>Cotinine level has been used to differentiate active smokers from nonsmokers because cotinine is widely considered to be the best marker for monitoring tobacco exposure in either actively or passively exposed individuals. However, as shown in <xref ref-type="table" rid="T3">Table 3</xref>, the information of smoking amount obtained from questionnaire showed better relationships with inflammatory biomarkers (TNF-&#x003b1;, <italic>p</italic>=0.18; and WBC, <italic>p</italic>&#x0003c;0.01, respectively) than urinary cotinine level (TNF-&#x003b1;, <italic>p</italic>=0.37; and WBC, <italic>p</italic>=0.04, respectively) after adjustment of age, sex, and BMI, although smoking amount and cotinine level showed good correlation (Pearson, correlation coefficient=0.56, <italic>p</italic>&#x0003c;0.01; Spearman, correlation coefficient=0.83, <italic>p</italic>&#x0003c;0.01; and Kendall, correlation coefficient=0.70, <italic>p</italic>&#x0003c;0.01, respectively).</p><p>The effects of smoking on serum TNF-&#x003b1; level and blood WBC count were evaluated after stratification according to the <italic>GSTM1</italic> or <italic>GSTP1</italic> gene polymorphism to estimate whether the <italic>GSTM1</italic> and <italic>GSTP1</italic> gene polymorphisms modify the relation between smoking and serum TNF-&#x003b1; level or blood WBC count. In the linear regression analysis after adjustment of age, sex, and BMI, none of the <italic>GSTM1</italic> and <italic>GSTP1</italic> genotypes showed statistically significant effect on the relation between serum TNF-&#x003b1; level or blood WBC count and smoking exposure measured by smoking amount or urinary cotinine level (all of four strata, <italic>p</italic>&#x0003e;0.1). Since the metabolism of the toxins from tobacco smoke is extremely complex, single gene may not have enough impact on inflammation. In an attempt to address this complexity, we constructed and analyzed composite genotypes (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="fig" rid="F2">2</xref>). Combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes in subjects with pack year or cotinine level over zero showed higher TNF-&#x003b1; level than the other genotype combinations, although the differences were not statistically significant (ANOVA, pack year, <italic>p</italic>=0.07; and cotinine, <italic>p</italic>=0.15, respectively) (<xref ref-type="fig" rid="F1">Fig. 1</xref>). This trend was also shown in linear regression (pack year, <italic>p</italic><sub>trend</sub>=0.07; and cotinine, <italic>p</italic><sub>trend</sub>=0.15, respectively). However, combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes in subjects with pack year or cotinine level over zero did not show higher WBC count than the other genotype combinations, although subjects with pack year or cotinine level over zero showed increased WBC count than those with pack year or cotinine level zero in all genotype combinations (ANOVA, pack year, <italic>p</italic>=0.34; and cotinine, <italic>p</italic>=0.15, respectively) (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>TNF-&#x003b1; protein has been known to play an important role in a variety of diseases through inflammatory reaction and tobacco smoke has been known to induce inflammation-related diseases including cancer (<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B11">11</xref>). Therefore, inflammationrelated diseases caused by smoking may be promoted through increase of TNF-&#x003b1; level. However, the effect of smoking on TNF-&#x003b1; level was inconsistent in previous reports. Kuschner and coworkers reported that smokers had higher level of pulmonary TNF-&#x003b1; than nonsmokers (<xref ref-type="bibr" rid="B6">6</xref>), but Keatings and coworkers did not show the elevated TNF-&#x003b1; level in asymptomatic smokers (<xref ref-type="bibr" rid="B25">25</xref>). Our data also did not support the significant association between smoking amount and TNF-&#x003b1; level. However, when we analyzed the effect of smoking on TNF-&#x003b1; level according to genotype combination, smoking showed marginally significant effect on TNF-&#x003b1; level in subjects with combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes in spite of low level of tobacco smoke exposure. Moreover, WBCs were significantly increased by smoking regardless of genotypes. These results indicate that smoking can increase the levels of inflammation biomarkers, particularly in subjects with combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes. The relationship between smoking and inflammation-induced carcinogenesis is biologically plausible. Oxidative stress such as the formation of reactive oxygen species (ROS) is a key component of inflammation, and they lead to damage of macromolecules such as DNA, protein, and lipid, eventually cancer when ROS are generated in large amounts (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Moreover, GST enzymes have been reported to protect against endogenous or exogenous oxidative damage (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). These facts support that GST enzymes may protect against inflammation through oxidative damage induced by toxic chemicals contained in tobacco smoke. Although host antioxidant defences such as GSTs detoxify ROS, individuals differ in their ability to deal with oxidant burden, and such differences are, in part, genetically determined (<xref ref-type="bibr" rid="B29">29</xref>). Inability to detoxify ROS due to genetic variation is likely to perpetuate the inflammatory process which could be associated with a variety of diseases.</p><p>We hypothesized that elevated TNF-&#x003b1; is a good indicator of inflammation caused by smoking and serum TNF-&#x003b1; level would be associated with GST polymorphisms in relation to smoking. The present study showed that subjects with the combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes have higher TNF-&#x003b1; level than those with the other genotype combinations. This result suggests that there are interactions between <italic>GSTM1</italic> and <italic>GSTP1</italic> genetic polymorphisms, thus subjects with the combination of <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotypes are more susceptible to smoking-induced inflammation than those with the other genotype combinations. The previous study by Ryberg and coworkers support the interaction between <italic>GSTM1</italic> and <italic>GSTP1</italic> genetic polymorphisms (<xref ref-type="bibr" rid="B30">30</xref>). In their study, when the effects of combined <italic>GSTM1</italic> and <italic>GSTP1</italic> genotypes on DNA adduct formation were examined, lung cancer patients with <italic>GSTM1</italic> null and <italic>GSTP1</italic> AG or GG genotype combinations had significantly higher carcinogen-derived DNA adduct level in lung tissue than those with the other genotype combinations. This genotype combination effect was not found in WBC count in our study. The reason may be that the elevation of WBC count may be relatively late and consequential event rather than causal event in inflammatory pathway while TNF-&#x003b1; is considered as a proinflammatory cytokine and a causal factor of inflammation because the binding of TNF-&#x003b1; to its receptors results in the activation of major transcription factors such as AP-1 and NFkB which in turn induce genes involved in acute and chronic inflammatory responses (<xref ref-type="bibr" rid="B9">9</xref>). Moreover, TNF-&#x003b1; may be induced through excessive oxidative stress by toxic chemicals contained in tobacco smoke although the level may be modified by GSTM1 and GSTP1 enzymes. For this reason, TNF-&#x003b1; may be more relevant as a biomarker indicating inflammation which could be associated with a variety of diseases than WBC count, although both TNF-&#x003b1; and WBC are indicators of inflammation.</p><p>In our study, questionnaire information of smoking showed better relationship with TNF-&#x003b1; level or WBC count than urinary cotinine level, although cotinine is widely considered to be the best marker for monitoring tobacco exposure. Study subjects sometimes intend to stop smoking before study and half life of cotinine in the body is very short (about 17 hr). Therefore, change of smoking habit before study may lead to the change of urinary cotinine level, which may undermine relationship between urinary cotinine level and TNF-&#x003b1; level or WBC count. In addition, our study showed borderline significance of smoking on TNF-&#x003b1; level, probably due to small sample size. Therefore, this study results should be confirmed through studies of larger subjects. In conclusion, our study findings suggest that smoking may induce inflammation measured as TNF-&#x003b1; level or WBC count and combinations of the <italic>GSTM1</italic> and <italic>GSTP1</italic> polymorphisms may modify the effect of smoking on serum TNF-&#x003b1; level, indicating genetic susceptibility to smoking-related diseases.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by the <funding-source>Ministry of Health and Welfare, Republic of Korea</funding-source> (grant no. <award-id>02-PJ1-PG1-CH03-0001</award-id>).</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaysen</surname><given-names>GA</given-names></name></person-group><article-title>Inflammation: cause of vascular disease and malnutrition in dialysis patients</article-title><source>Semin Nephrol</source><year>2004</year><volume>24</volume><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">15490405</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names><suffix>Jr</suffix></name></person-group><article-title>Asthma</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">11172168</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">11229684</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RA</given-names></name><name><surname>Dubois</surname><given-names>RN</given-names></name></person-group><article-title>Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</article-title><source>Nature Rev Cancer</source><year>2001</year><volume>1</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11900248</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuschner</surname><given-names>WG</given-names></name><name><surname>D'Alessandro</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>H</given-names></name><name><surname>Blanc</surname><given-names>PD</given-names></name></person-group><article-title>Dose-dependent cigarette smoking-related inflammatory responses in healthy adults</article-title><source>Eur Respir J</source><year>1996</year><volume>9</volume><fpage>1989</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">8902455</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KR</given-names></name><name><surname>Uyeminami</surname><given-names>DL</given-names></name><name><surname>Kodavanti</surname><given-names>UP</given-names></name><name><surname>Crapo</surname><given-names>JD</given-names></name><name><surname>Chang</surname><given-names>LY</given-names></name><name><surname>Pinkerton</surname><given-names>KE</given-names></name></person-group><article-title>Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant</article-title><source>Free Radic Biol Med</source><year>2002</year><volume>33</volume><fpage>1106</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">12374622</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusznak</surname><given-names>C</given-names></name><name><surname>Sapsford</surname><given-names>RJ</given-names></name><name><surname>Devalia</surname><given-names>JL</given-names></name><name><surname>Shah</surname><given-names>SS</given-names></name><name><surname>Hewitt</surname><given-names>EL</given-names></name><name><surname>Lamont</surname><given-names>AG</given-names></name><name><surname>Davies</surname><given-names>RJ</given-names></name><name><surname>Lozewicz</surname><given-names>S</given-names></name></person-group><article-title>Interaction of cigarette smoke and house dust mite allergens on inflammatory mediator release from primary cultures of human bronchial epithelial cells</article-title><source>Clin Exp Allergy</source><year>2001</year><volume>31</volume><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">11251624</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB</article-title><source>Ann Rheum Dis</source><year>2000</year><volume>59</volume><fpage>i6</fpage><lpage>i16</lpage><pub-id pub-id-type="pmid">11053079</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>A</given-names></name><name><surname>Yatsunami</surname><given-names>J</given-names></name><name><surname>Suganuma</surname><given-names>M</given-names></name><name><surname>Okabe</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Fujiki</surname><given-names>H</given-names></name></person-group><article-title>Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>1982</fpage><lpage>1985</lpage><pub-id pub-id-type="pmid">8481899</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Porat</surname><given-names>RM</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name><name><surname>Abramovitch</surname><given-names>R</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Kasem</surname><given-names>S</given-names></name><name><surname>Gutkovich-Pyest</surname><given-names>E</given-names></name><name><surname>Urieli-Shoval</surname><given-names>S</given-names></name><name><surname>Galun</surname><given-names>E</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group><article-title>NF-kappaB functions as a tumour promoter in inflammation-associated cancer</article-title><source>Nature</source><year>2004</year><volume>431</volume><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">15329734</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szlosarek</surname><given-names>PW</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><article-title>Tumor necrosis factor a: a potential target for the therapy of solid tumors</article-title><source>Lancet Oncol</source><year>2003</year><volume>4</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">12965278</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamsson</surname><given-names>J</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Mellander</surname><given-names>L</given-names></name></person-group><article-title>Tumor necrosis factoralpha in malignant disease</article-title><source>Am J Pediatr Hematol Oncol</source><year>1993</year><volume>15</volume><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">8214357</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Grove</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>BL</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name></person-group><article-title>Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2001</year><volume>21</volume><fpage>1065</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">11397721</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Sharrett</surname><given-names>AR</given-names></name><name><surname>Lindberg</surname><given-names>G</given-names></name><name><surname>Savage</surname><given-names>PJ</given-names></name><name><surname>Offenbacher</surname><given-names>S</given-names></name><name><surname>Azambuja</surname><given-names>MI</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name></person-group><article-title>Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1649</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">10335783</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churg</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Tai</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>JL</given-names></name></person-group><article-title>Tumor necrosis factor-&#x003b1; is central to acute cigarette smoke-induced inflammation and connective tissue breakdown</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">12231496</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Stanley</surname><given-names>LA</given-names></name><name><surname>Sim</surname><given-names>E</given-names></name><name><surname>Strange</surname><given-names>RC</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>Metabolic polymorphisms and cancer susceptibility</article-title><source>Cancer Surv</source><year>1995</year><volume>25</volume><fpage>27</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">8718512</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushmore</surname><given-names>TH</given-names></name><name><surname>Pickett</surname><given-names>CB</given-names></name></person-group><article-title>Glutathione S-transferases, structure, regulation and therapeutic implications</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>11475</fpage><lpage>11478</lpage><pub-id pub-id-type="pmid">8505281</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Pare</surname><given-names>PD</given-names></name><name><surname>Sandford</surname><given-names>AJ</given-names></name></person-group><article-title>Glutathione S-transferase variants and their interaction with smoking on lung function</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><fpage>388</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15184197</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Pulford</surname><given-names>DJ</given-names></name></person-group><article-title>The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance</article-title><source>Crit Rev Biochem Mol Biol</source><year>1995</year><volume>30</volume><fpage>445</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">8770536</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saarikoski</surname><given-names>ST</given-names></name><name><surname>Voho</surname><given-names>A</given-names></name><name><surname>Reinikainen</surname><given-names>M</given-names></name><name><surname>Anttila</surname><given-names>S</given-names></name><name><surname>Karjalainen</surname><given-names>A</given-names></name><name><surname>Malaveille</surname><given-names>C</given-names></name><name><surname>Vainio</surname><given-names>H</given-names></name><name><surname>Husgafvel-Pursiainen</surname><given-names>K</given-names></name><name><surname>Hirvonen</surname><given-names>A</given-names></name></person-group><article-title>Combined effect of polymorphic GST genes on individual susceptibility to lung cancer</article-title><source>Int J Cancer</source><year>1998</year><volume>77</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">9679751</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidegard</surname><given-names>J</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name><name><surname>Markowitz</surname><given-names>MM</given-names></name><name><surname>Roush</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>DG</given-names></name><name><surname>Beattie</surname><given-names>EJ</given-names></name></person-group><article-title>Isoenzyme(s) of glutathione S-transferase (class mu) as a marker for the susceptibility to lung cancer. A follow-up study</article-title><source>Carcinogenesis</source><year>1990</year><volume>11</volume><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">2295125</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Saieva</surname><given-names>C</given-names></name><name><surname>Gemma</surname><given-names>S</given-names></name><name><surname>Masala</surname><given-names>G</given-names></name><name><surname>Gomez-Miguel</surname><given-names>MJ</given-names></name><name><surname>Luzzi</surname><given-names>I</given-names></name><name><surname>D'Errico</surname><given-names>M</given-names></name><name><surname>Matullo</surname><given-names>G</given-names></name><name><surname>Ozzola</surname><given-names>G</given-names></name><name><surname>Manetti</surname><given-names>R</given-names></name><name><surname>Nesi</surname><given-names>G</given-names></name><name><surname>Sera</surname><given-names>F</given-names></name><name><surname>Zanna</surname><given-names>I</given-names></name><name><surname>Dogliotti</surname><given-names>E</given-names></name><name><surname>Testai</surname><given-names>E</given-names></name></person-group><article-title><italic>GSTT1</italic> and <italic>GSTM1</italic> gene polymorphisms and gastric cancer in a high-risk italian population</article-title><source>Int J Cancer</source><year>2005</year><volume>115</volume><fpage>284</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">15688399</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimniak</surname><given-names>P</given-names></name><name><surname>Nanduri</surname><given-names>B</given-names></name><name><surname>Pikula</surname><given-names>S</given-names></name><name><surname>Bandorowicz-Pikula</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>SS</given-names></name><name><surname>Srivastava</surname><given-names>SK</given-names></name><name><surname>Awasthi</surname><given-names>S</given-names></name><name><surname>Awasthi</surname><given-names>YC</given-names></name></person-group><article-title>Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties</article-title><source>Eur J Biochem</source><year>1994</year><volume>224</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">7925413</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keatings</surname><given-names>VM</given-names></name><name><surname>Collins</surname><given-names>PD</given-names></name><name><surname>Scott</surname><given-names>DM</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Difference in interleukin-8 and TNF&#x003b1; in induced sputum from patients with chronic obstructive pulmonary disease or asthma</article-title><source>Am J Respir Crit Med</source><year>1996</year><volume>153</volume><fpage>530</fpage><lpage>534</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C</given-names></name><name><surname>De Castro</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>E</given-names></name><name><surname>Redondo</surname><given-names>A</given-names></name><name><surname>Sereno</surname><given-names>M</given-names></name><name><surname>Garcia-Cabezas</surname><given-names>MA</given-names></name><name><surname>Vara</surname><given-names>JA</given-names></name><name><surname>Dominguez-Caceres</surname><given-names>A</given-names></name><name><surname>Perona</surname><given-names>R</given-names></name><name><surname>Gonzalez-Baron</surname><given-names>M</given-names></name></person-group><article-title>Implication of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain)</article-title><source>Cancer Causes Control</source><year>2004</year><volume>15</volume><fpage>707</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">15280629</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakim</surname><given-names>IA</given-names></name><name><surname>Harris</surname><given-names>RB</given-names></name><name><surname>Chow</surname><given-names>HH</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>IU</given-names></name></person-group><article-title>Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: role of glutathione S-transferase genotypes</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2004</year><volume>13</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">14973088</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Strange</surname><given-names>RC</given-names></name></person-group><article-title>Potential contribution of the glutathione S-transferase supergene family to resistence to oxidative stress</article-title><source>Free Radic Res</source><year>1995</year><volume>22</volume><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">7757196</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Reactive oxygen species and airway inflammation</article-title><source>Free Radic Biol Med</source><year>1990</year><volume>9</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">2272532</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryberg</surname><given-names>D</given-names></name><name><surname>Skaug</surname><given-names>V</given-names></name><name><surname>Hewer</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>DH</given-names></name><name><surname>Harries</surname><given-names>LW</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Ogreid</surname><given-names>D</given-names></name><name><surname>Ulvik</surname><given-names>A</given-names></name><name><surname>Vu</surname><given-names>P</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name></person-group><article-title>Genotypes of glutathione S-transferase M1 and P1 and their significance for lung DNA adduct levels and caner risk</article-title><source>Carcinogenesis</source><year>1997</year><volume>18</volume><fpage>1285</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">9230269</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Serum TNF-&#x003b1; levels according to combinations of <italic>GSTM1</italic> and <italic>GSTP1</italic> polymorphisms in strata divided by pack year (<bold>A</bold>) or urinary cotinine level (<bold>B</bold>). M1, <italic>GSTM1</italic> present; M1<sup>*</sup>, <italic>GSTM1</italic> null; P1: <italic>GSTP1</italic> AA; P1<sup>*</sup>, <italic>GSTP1</italic> AG or GG. ANOVA was used to compare the means of TNF-&#x003b1; levels according to genotype combinations in strata divided by pack year (pack year=0, <italic>p</italic>=0.40; and pack year &#x0003e;0, <italic>p</italic>=0.07, respectively) or cotinine level (cotinine=0, <italic>p</italic>=0.41; and cotinine &#x0003e;0, <italic>p</italic>=0.15, respectively). The number in each bar indicates number of subjects included in strata of each genotype combination in smoker and nonsmoker.</p></caption><graphic xlink:href="jkms-21-1021-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Blood WBC counts according to combinations of <italic>GSTM1</italic> and <italic>GSTP1</italic> polymorphisms in strata divided by pack year (<bold>A</bold>) or urinary cotinine level (<bold>B</bold>). M1, <italic>GSTM1</italic> present; M1<sup>*</sup>, <italic>GSTM1</italic> null; P1: <italic>GSTP1</italic> AA; P1<sup>*</sup>, <italic>GSTP1</italic> AG or GG. ANOVA was used to compare the means of WBC counts according to genotype combinations in strata divided by pack year (pack year=0, <italic>p</italic>=0.77; and pack year &#x0003e;0, <italic>p</italic>=0.34, respectively) or cotinine level (cotinine=0, <italic>p</italic>=0.95; and cotinine &#x0003e;0, <italic>p</italic>=0.15, respectively). The number in each bar indicates number of subjects included in strata of each genotype combination in smoker and nonsmoker.</p></caption><graphic xlink:href="jkms-21-1021-g002"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of the study population according to smoking status</p></caption><graphic xlink:href="jkms-21-1021-i001"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>-value from chi-square test for categorical variables or t-test for continuous variables analysis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Total serum TNF-&#x003b1; levels and blood WBC counts according to subject characteristics and genotypes</p></caption><graphic xlink:href="jkms-21-1021-i002"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>-value from t-test, <sup>&#x02020;</sup>BMI dichotomized by median value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effects of smoking amount or cotinine level on serum TNF-&#x003b1; level or blood WBC count</p></caption><graphic xlink:href="jkms-21-1021-i003"/><table-wrap-foot><fn><p><sup>*</sup>Mean and <sup>&#x02020;</sup><italic>p</italic>-trend were obtained by linear regression after controlling for age, sex, and BMI.</p></fn></table-wrap-foot></table-wrap></floats-group></article>